What question did this study set out to answer?

April 12, 2026Open Access

Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Key Points

This research aims to evaluate the efficacy and safety of oxymetazoline hydrochloride 0.1% in treating blepharoptosis.
Phase 3 clinical trial design
Comparison of oxymetazoline 0.1% treatment to placebo
Duration of treatment assessed over six months
Measurement of MRD-1 as a primary outcome
Significant increase in MRD-1 after 14 days of oxymetazoline treatment compared to placebo
No loss of effect observed after six months of treatment
No significant safety concerns reported during the study

Abstract

Fourteen days of OMZ 0.1% treatment significantly increased MRD-1 versus placebo. There was no loss of effect after 6 months of treatment and no significant safety concerns.

Bookmark

View Full Paper